Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
masofermin
- Development stage
- Preclinical
- Lead developer
- XenoTherapeutics
- Modality
- Small Molecules
01
Overview
Masofermin is a clinical-stage small molecule developed by ESSA Pharma for the treatment of prostate cancer. It was identified as the lead asset of ESSA Pharma prior to the company's acquisition by XenoTherapeutics.
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on masofermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on masofermin.